sb 216763 has been researched along with Parkinson Disease, Secondary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yin, M; Zhang, MH; Zhang, XM | 1 |
| Akaike, A; Hongo, H; Izumi, Y; Kihara, T; Kume, T; Niidome, T; Sugimoto, H | 1 |
2 other study(ies) available for sb 216763 and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Cell-based assays for Parkinson's disease using differentiated human LUHMES cells.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Cell Death; Cell Differentiation; Cell Line; Cyclin-Dependent Kinase 2; Drug Evaluation, Preclinical; Glycogen Synthase Kinase 3; Humans; Indoles; Maleimides; Mesencephalon; Neurons; Neuroprotective Agents; Parkinson Disease; Parkinson Disease, Secondary | 2014 |
Glycogen synthase kinase-3β activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization.
Topics: Cell Line, Tumor; Electron Transport Complex I; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Microtubules; Paclitaxel; Parkinson Disease, Secondary; Phosphorylation; Reactive Oxygen Species; Rotenone; tau Proteins; Tubulin Modulators | 2012 |